Table 1.
Clinical characteristics of study cohort.
| Group | n | Age median (IQR) | CD4/mm3 median (IQR) | VL cp/ml median (IQR) | ART baseline | ART > baseline |
|---|---|---|---|---|---|---|
| Pediatric slow progressors total (PSP) | 23 | 10.2 (7–13.1) | 752 (450–906) | 37,600 (6,200–88,000) | no | no/yes |
| PSP subsequently on treatment/ Future progressors (FP) | 11 | 12.4 (7–13.7) | 704 (450–906) | 59,000 (8000–130,000) | no | yes |
| PSP treatment naïve (PSPN) | 12 | 9.85 (7.28–12.2) | 796 (550–922.8) | 24,000 (1015–57,000) | no | no |
| Pediatric progressors | 10 | 10.65 (9–15.18) | 233.5 (122.5–342.8) | 120,000 (17,700–120,000) | no | yes |
| Pediatric healthy controls | 20 | 13.15 (10–15.5) | N/A | N/A | N/A | N/A |
Overview of study subjects used for the different experiments in this study. Not for all shown subjects all experiments could be performed. All HIV-infected paediatric individuals were infected by vertical transmission.
N/A, not applicable.N/D, not done.